OptoCeutics Launches ALZLIGHT Stage III Clinical Trial
Study on the Effect of 40 Hz Non-Invasive Light Therapy System
The ALZLIGHT STAGE III Study is a continuation of the ALZLIGHT Pilot – Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System.
As with the first two stages, this study will examine whether entrainment of 40 Hz neural oscillation by novel 40 Hz Invisible Spectral Flicker is a potential therapy for Alzheimer’s Disease. In order to examine this, 62 patients with mild to moderate Alzheimer’s Disease will be recruited. The patients will be exposed to the Non-Invasive Light Therapy System for 1 hour a day for 6 months. The effect will be measured by a combination of electroencephalography, cognitive testing, functional magnetic resonance imaging, magnetic resonance spectroscopy and actigraphy.
Potential subjects located in Denmark should email firstname.lastname@example.org for trial participation enquiries.